Eli Lilly (LLY) experienced a significant surge of 7.2% in early trading on Wednesday. The company reported fourth-quarter revenue of $19.29 billion, marking a 43% increase, alongside an adjusted earnings per share of $7.54. Fueled by the strong performance of Zepbound and Mounjaro, Eli Lilly raised its 2026 revenue guidance to a range of $80 to $83 billion and increased its earnings per share projection to between $33.50 and $35.00.